Member Info for lostinspace69

Hugely undervalued and 2.5% divided yield.

Not looking good

I can see a discounted placing in the coming sessions. Just saying

What kind of good news are you thinking ?

They extended the deadline. I’d imagine quite a few people in same boat. I kept waiting and hoping but today is the last chance for me to sell, settle and get the money over to them in time

900k sell earlier was me. People often ask why the hell are people selling at these levels. For me it’s very simple, I have to pay HMRC £135k by this Friday. Still holding 10m and hoping I won’t have to sell any of those, but sometimes we don’t have a choice in these matters. Good luck all.

https://www.nytimes.com/2022/01/14/health/saliva-testing-coronavirus-omicron.html

Article highlights;

“The virus shows up first in your mouth and throat,” Dr. Milton said. “That means that the approach we’re taking to testing has problems.”

Collecting samples of saliva, or swabbing the inside of the mouth, could help identify people who are infected with the virus days earlier than nasal swabs do, some research suggests.

“There’s been a growing body of evidence that at the very least, saliva performs well — it’s as good as, if not better, when it’s collected properly, when it’s processed properly,” Dr. Wyllie said.

Evidence also emerged that the virus tended to appear in saliva before it built up in the nose, suggesting that saliva samples might be the best way to detect infections early.

Dr. Milton and his colleagues recently found that in the three days before symptoms appear and the two days after, saliva samples contained about three times as much virus as nasal samples and were 12 times as likely to produce a positive P.C.R. result.

Saliva’s advantages may be more pronounced with Omicron, which appears to replicate more quickly in the upper respiratory tract and have a shorter incubation period than earlier variants.

Some experts have also theorized that Omicron may be better at replicating in the cells of the mouth and throat than other variants have been.

A team of South African researchers recently found that while nasal swabs performed better than saliva swabs when detecting the Delta variant, the opposite was true for Omicron.

In Britain, some at-home tests require swabbing both the throat and the nose, an approach that may be worth pursuing, experts said.

ETA 6 months. Forget LFT. There will be no Covid-19 test from Avacta. Missed the boat.

Wow. The sheer gall of it, and on Christmas Eve. I’m afraid the writing has been on the wall a long time here. So glad I exited for a small loss. Absolutely appalling and feel for those who’ve lost out here.

Dimvestor - is it worth attending? Is there an opportunity to present questions? thx

I agree with your analysis. I think I’ll sell into any strength over the coming days, as this looks like it’ll roll on for a while

AutomationGuru Agreed on all of that. So, how do you see this playing out from here?

Wow. So pleased I took a loss on this at 12p

Other bidders will emerge. Give it time

Looks like a stitch up. BOD clearly incentivised to push this deal through, which is clearly a very bad deal for shareholders and should not be supported.

currently up 18%. not much interest on here, but while everyone chases rainbows, here is a dead cert unicorn.

Outlook

The Group has continued to trade well since the end of H1 21, with further year on year revenue and Adjusted EBITDA growth in July and August 2021.

Given the H1 21 results and the strong pipeline that we see for the remainder of FY21, the Board's current expectation is that full year FY21 revenue will now be in the range of £47m-£50m with an Adjusted EBITDA margin in the 30-32% range. Previously our expectation was to achieve revenues at the upper end of the £44m-47m range, at c.29% EBITDA margin. We are pleased to update this.

By sustaining focus on exceptional delivery for our clients and progressing all elements of our four-pillar growth strategy, the Board believes that the Group is well positioned for further growth and success for the remainder of the year and beyond.

Elixirr is pleased to report the following financial highlights for the Group for H1 21:

· A 77% increase in revenue compared to H1 2020, with revenue totalling £24.0m and record revenue in five of the six months in the period

· Strong organic revenue growth of 45%, including growth in excess of 100% in our US business, and material contributions from the two acquisitions made in H2 20 and H1 21

· A 78% increase in Adjusted EBITDA[1] compared to H1 20, totalling £8.1m, and maintaining our strong track record of profitability with an Adjusted EBITDA margin of 33.8%

· A 145% increase in profit before tax, totalling £6.4m (H1 20: £2.6m)

· Robust and healthy balance sheet with net cash of £21.1m and no debt[2]

· Strong pipeline for the remainder of the year leading to the second upgrade in board expectations for FY 21 of c.£47m-£50m of revenue with an Adjusted EBITDA[1] margin in the 30-32% range

How many times have we thought or heard that?! Boris this, Trump that. Here we are 18 months later and still hanging on and clutching at straws.

Good to hear from you Paddy. Sitting on my hands here and never been more confident or more excited.